# Study of Plasma Tumor-promoting Factors and Immune Function After Laparotomy, Cytoreductive Surgery and HIPEC vs. PIPAC in Patients With Peritoneal Metastasis

> **NCT04122885** · — · UNKNOWN · sponsor: **University Hospital Tuebingen** · enrollment: 60 (estimated)

## Conditions studied

- Peritoneal Cancer
- Chemotherapy-Induced Change

## Interventions

- **COMBINATION_PRODUCT:** PIPAC with oxaliplatin
- **PROCEDURE:** Cytoreductive surgery and Hyperthermic IntraPeritoneal Chemotherapy

## Key facts

- **NCT ID:** NCT04122885
- **Lead sponsor:** University Hospital Tuebingen
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-10-01
- **Primary completion:** 2020-09-30
- **Final completion:** 2022-09-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2019-10-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04122885

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04122885, "Study of Plasma Tumor-promoting Factors and Immune Function After Laparotomy, Cytoreductive Surgery and HIPEC vs. PIPAC in Patients With Peritoneal Metastasis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04122885. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*